Synlogic
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 6
- Market Cap
- $17.4M
- Website
- http://www.synlogictx.com
- Introduction
Synlogic, Inc. is a biopharmaceutical company which engages in the discovery and development of synthetic biotic medicines. It focuses on phenylketonuria, enteric hyperoxaluria, immuno-oncology solid tumors, inflammatory bowel disease, and vaccines and other inflammatory programs. The company was founded by James J. Collins and Timothy K. Lu on December 20, 2007 and is headquartered in Cambridge, MA.
Synlogic's Novel Probiotic Therapy Shows Promise in Phase 2 PKU Trial, Advancing to Phase 3
• Synlogic's engineered probiotic SYNB1934 demonstrated a significant 34% reduction in phenylalanine levels in phenylketonuria patients during Phase 2 trials, outperforming its predecessor SYNB1618.
• The experimental therapy showed a 42% reduction in plasma phenylalanine among responders, with 60% of patients achieving clinically meaningful improvements in their condition.
• Phase 3 trials for SYNB1934 are scheduled to begin in early 2023, offering potential hope for PKU patients who have limited treatment options with current therapies.
Tulisokibart Shows Promise in Treating Moderate to Severe Ulcerative Colitis
• A Phase 2 trial of tulisokibart, an anti-TL1A monoclonal antibody, demonstrated superior efficacy compared to placebo in inducing clinical remission in patients with moderate to severe ulcerative colitis.
• The study utilized a genetic-based diagnostic test to identify patients more likely to respond to tulisokibart, showing improved remission rates in this subgroup.
• Tulisokibart modulates inflammation and the body's anti-inflammatory mechanisms, offering a novel approach compared to existing IBD treatments that can exacerbate inflammation.
• The safety profile of tulisokibart appeared comparable to placebo, with similar rates of adverse events, supporting its potential as a valuable new treatment option.
© Copyright 2025. All Rights Reserved by MedPath